Your browser doesn't support javascript.
loading
Changes in Circulating Adipokine Levels in COVID-19 Patients.
Wikar, Tomasz; Rubinkiewicz, Mateusz; Stygar, Dominika; Chelmecka, Elzbieta; Popiela, Urszula; Michal, Wysocki; Tylec, Piotr; Maziarz, Barbara; Kukla, Michal.
Afiliação
  • Wikar T; 2nd Department of General Surgery, Jagiellonian University Medical College, 31-066 Kraków, Poland.
  • Rubinkiewicz M; Department of Medical Education, Jagiellonian University Medical College, 31-066 Krakow, Poland.
  • Stygar D; 2nd Department of General Surgery, Jagiellonian University Medical College, 31-066 Kraków, Poland.
  • Chelmecka E; Department of Physiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 41-808 Zabrze, Poland.
  • Popiela U; Department of Medical Statistic, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 40-055 Sosnowiec, Poland.
  • Michal W; 2nd Department of General Surgery, Jagiellonian University Medical College, 31-066 Kraków, Poland.
  • Tylec P; Department of General Surgery and Surgical Oncology, Ludwik Rydygier Memorial Hospital, 31-826 Kraków, Poland.
  • Maziarz B; Faculty of Medicine, Jagiellonian University Medical College, 31-066 Kraków, Poland.
  • Kukla M; Department of Diagnostics, University Hospital, 30-688 Kraków, Poland.
J Clin Med ; 13(16)2024 Aug 14.
Article em En | MEDLINE | ID: mdl-39200926
ABSTRACT

Objective:

The COVID-19 pandemic has posed significant global health challenges. Despite extensive research efforts, the inflammatory response triggered by SARS-CoV-2 remains to be further explored and understood. Our study aims to examine the changes in serum concentrations of pro-inflammatory adipokines-visfatin and leptin-in COVID-19 patients in relation to a healthy control group. Patients/Materials/Subjects and

Methods:

The study consisted of forty COVID-19 patients and twenty-four healthy patients in the control group. Two serum samples were collected upon admission and on the seventh day of hospitalization. Concentrations of visfatin and leptin in the serum, alongside routine biochemical parameters, were measured using enzyme immunoassay or enzyme-linked immunosorbent assay kits. The Shapiro-Wilk test was used to assess normality. Differences between independent groups were compared using the Mann-Whitney U test and Kruskal-Wallis ANOVA. Correlations were evaluated with Spearman's rank correlation coefficient.

Results:

Our findings revealed significantly lower visfatin levels in COVID-19 patients compared to the control group upon admission (4.29 ng/mL, (3.0-6.88 ng/mL) vs. 37.16 ng/mL (24.74-50.12 ng/mL), p < 0.001 for visfatin 1 and 52.05 ng/mL, (31.2-69.66 ng/mL) vs. 37.16 ng/mL (24.74-50.12 ng/mL), p = 0.048 for visfatin 2). The visfatin level of COVID-19 patients returned to the normal levels, established in the control group. However, there was no significant difference in leptin levels between the two groups (p = 0.270 for leptin 1 and p = 0.129 for leptin 2). There was a positive correlation between BMI and leptin concentration (r = 0.66 and p = 0.00). Moreover, it was discovered that COVID-19 independently reduces visfatin levels during the first day of illness.

Conclusions:

The results of our research suggest that the onset of COVID-19 infection is correlated to visfatin levels. Association with leptin levels remains inconclusive. Further research is imperative to elucidate the intricate role of visfatin and leptin in SARS-CoV-2 infection and their potential as biomarkers for COVID-19 severity and prognosis.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article